Table 4 Univariable and multivariable analyses of prognostic factors in terms of progression-free survival (PFS) and overall survival (OS).

From: CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

 

Progression-free survival

Overall survival

Univariable analysis

Multivariable analysis

Univariable analysis

Multivariable analysis

HR

95% CI

P-value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P-value

Elevated CEA change above the cut-off value (vs below the cut-off value)

1.25

1.10–1.41

 < 0.001

1.24

1.09–1.41

 < 0.001

1.29

1.10–1.51

 < 0.001

1.28

1.09–1.51

0.003

Female (vs male)

0.99

0.87–1.11

0.82

   

1.02

0.87–1.19

0.82

   

Age ≥ 60 years (vs < 60 years)

1.07

0.94–1.20

0.26

1.04

0.92–1.18

0.45

1.07

0.91–1.25

0.39

1.06

0.90–1.24

0.48

Tumor grade

 Moderately differentiated (vs well differentiated)

1.0

0.79–1.25

0.97

0.97

0.77–1.24

0.86

0.88

0.66–1.18

0.4

0.86

0.64–1.14

0.31

 Poorly differentiated (vs well differentiated)

1.34

1.0–1.81

0.052

1.29

0.95–1.74

0.09

1.58

1.1–2.29

0.014

1.43

0.98–2.08

0.06

Primary tumor location, left (vs right)

0.86

0.75–0.99

0.04

0.94

0.81–1.09

0.44

0.77

0.64–0.93

0.006

0.86

0.71–1.04

0.14

BRAF mutant (vs wild type)

1.34

1.01–1.78

0.03

1.41

1.03–1.93

0.02

2.05

1.46–2.88

 < 0.001

1.92

1.31–2.80

 < 0.001

KRAS mutant (vs wild type)

1.04

0.92–1.18

0.48

   

1.06

0.91–1.25

0.44

   

NRAS mutant (vs wild type)

0.9

0.53–1.51

0.69

   

1.79

0.55–5.81

0.33

   

Deficient MMR (vs proficient MMR)

1.26

0.89–1.80

0.2

   

1.54

1.01–2.34

0.045

   

MSI high (vs MSS or MSI low)

1.9

1.15–3.45

0.014

   

1.49

0.74–2.99

0.27

   
  1. HR, hazard ratio; CI, confidence interval; MMR, mismatch repair; MSI, microsatellite instability.
Back to article page